Related Experiment Video
Updated: Jun 13, 2026

08:49
Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
Published on: September 23, 2015
Post-mortem (re)distribution of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"): human and animal data
Els A De Letter1, Christophe P Stove, Willy E Lambert
1Forensic Institute, Ghent University, Belgium.
Current Pharmaceutical Biotechnology
|April 28, 2010
Summary
Postmortem redistribution of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) affects blood concentrations. Peripheral blood sampling is essential for accurate MDMA quantification in forensic cases.
Area of Science:
- Forensic Toxicology
- Pharmacology
Background:
- 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) is a widely used recreational drug with known toxicological implications.
- Understanding MDMA distribution and redistribution is crucial for accurate postmortem interpretation.
Purpose of the Study:
- To analyze the distribution and postmortem redistribution of MDMA.
- To compare animal data with human fatalities to understand MDMA's behavior after death.
- To establish reliable methods for postmortem MDMA quantification.
Main Methods:
- Comparison of animal experimental data with reported human MDMA fatalities.
- Analysis of MDMA concentrations in various biological matrices (cardiac blood, central organs, peripheral blood, vitreous humor, iliopsoas muscle).
- Evaluation of factors influencing postmortem redistribution, such as postmortem interval and putrefaction.
Main Results:
- Animal data generally paralleled human MDMA-related fatalities.
- MDMA exhibits significant postmortem redistribution due to its properties, leading to high concentrations in central blood and organs.
- Redistribution is more pronounced at longer postmortem intervals and with putrefaction.
Conclusions:
- Peripheral blood sampling (e.g., femoral vein) is compulsory for reliable postmortem MDMA quantification.
- Vitreous humor and iliopsoas muscle may serve as alternative matrices when peripheral blood is unavailable.
- Establishing a "safe" or "therapeutic" blood MDMA level is currently impossible due to individual susceptibility variations.

